Goldman Sachs’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $9.13M | Sell |
126,942
-20,851
| -14% | -$1.19M | ﹤0.01% | 3143 |
|
|
2025
Q4 | $6.25M | Buy |
147,793
+70,738
| +92% | +$3.96M | ﹤0.01% | 3541 |
|
|
2025
Q3 | $4.38M | Buy |
77,055
+14,605
| +23% | +$483K | ﹤0.01% | 3768 |
|
|
2025
Q2 | $1.61M | Buy |
62,450
+27,026
| +76% | +$303K | ﹤0.01% | 4345 |
|
|
2025
Q1 | $361K | Sell |
35,424
-13,068
| -27% | -$171K | ﹤0.01% | 5374 |
|
|
2024
Q4 | $676K | Sell |
48,492
-70,404
| -59% | -$1.24M | ﹤0.01% | 5067 |
|
|
2024
Q3 | $2.32M | Buy |
118,896
+1,063
| +0.9% | +$20.3K | ﹤0.01% | 4023 |
|
|
2024
Q2 | $2.19M | Buy |
117,833
+70,479
| +149% | +$1.49M | ﹤0.01% | 3848 |
|
|
2024
Q1 | $664K | Sell |
47,354
-10,237
| -18% | -$107K | ﹤0.01% | 4592 |
|
|
2023
Q4 | $488K | Sell |
57,591
-10,840
| -16% | -$82.1K | ﹤0.01% | 4772 |
|
|
2023
Q3 | $611K | Sell |
68,431
-18,394
| -21% | -$177K | ﹤0.01% | 4554 |
|
|
2023
Q2 | $749K | Buy |
86,825
+16,690
| +24% | +$178K | ﹤0.01% | 4523 |
|
|
2023
Q1 | $739K | Sell |
70,135
-2,131
| -3% | -$64.5K | ﹤0.01% | 4600 |
|
|
2022
Q4 | $2.45M | Sell |
72,266
-1,242
| -2% | -$60.1K | ﹤0.01% | 3784 |
|
|
2022
Q3 | $3.53M | Buy |
73,508
+26,716
| +57% | +$1.59M | ﹤0.01% | 3461 |
|
|
2022
Q2 | $2.67M | Buy |
46,792
+14,029
| +43% | +$885K | ﹤0.01% | 3789 |
|
|
2022
Q1 | $2.65M | Buy |
32,763
+5,710
| +21% | +$845K | ﹤0.01% | 3982 |
|
|
2021
Q4 | $5.48M | Sell |
27,053
-3,569
| -12% | -$774K | ﹤0.01% | 3314 |
|
|
2021
Q3 | $8.25M | Sell |
30,622
-10,470
| -25% | -$2.52M | ﹤0.01% | 2907 |
|
|
2021
Q2 | $10.6M | Buy |
41,092
+10,427
| +34% | +$2.89M | ﹤0.01% | 2642 |
|
|
2021
Q1 | $9.2M | Sell |
30,665
-37,951
| -55% | -$11.8M | ﹤0.01% | 2640 |
|
|
2020
Q4 | $17.5M | Buy |
68,616
+6,226
| +10% | +$1.61M | ﹤0.01% | 1979 |
|
|
2020
Q3 | $15.5M | Sell |
62,390
-48,696
| -44% | -$15.3M | ﹤0.01% | 1944 |
|
|
2020
Q2 | $38.6M | Sell |
111,086
-9,844
| -8% | -$3.07M | 0.01% | 1174 |
|
|
2020
Q1 | $32.4M | Sell |
120,930
-9,332
| -7% | -$2.89M | 0.01% | 1165 |
|
|
2019
Q4 | $42.2M | Buy |
130,262
+44,142
| +51% | +$12.8M | 0.01% | 1277 |
|
|
2019
Q3 | $23.5M | Buy |
86,120
+28,248
| +49% | +$10.4M | 0.01% | 1651 |
|
|
2019
Q2 | $30.9M | Buy |
57,872
+5,069
| +10% | +$2.54M | 0.01% | 1512 |
|
|
2019
Q1 | $26.6M | Sell |
52,803
-5,630
| -10% | -$3.34M | 0.01% | 1633 |
|
|
2018
Q4 | $28.8M | Sell |
58,433
-17,967
| -24% | -$10.8M | 0.01% | 1504 |
|
|
2018
Q3 | $69.9M | Sell |
76,400
-19,912
| -21% | -$17M | 0.02% | 990 |
|
|
2018
Q2 | $70.5M | Sell |
96,312
-3,866
| -4% | -$4.46M | 0.02% | 979 |
|
|
2018
Q1 | $160M | Buy |
100,178
+57,969
| +137% | +$74.7M | 0.04% | 529 |
|
|
2017
Q4 | $37.8M | Sell |
42,209
-21,059
| -33% | -$12.5M | 0.01% | 1487 |
|
|
2017
Q3 | $22.8M | Buy |
63,268
+9,979
| +19% | +$3.12M | 0.01% | 1871 |
|
|
2017
Q2 | $15.6M | Buy |
53,289
+10,393
| +24% | +$3M | ﹤0.01% | 2146 |
|
|
2017
Q1 | $15.1M | Buy |
42,896
+10,893
| +34% | +$2.45M | ﹤0.01% | 2097 |
|
|
2016
Q4 | $5.89M | Sell |
32,003
-24,019
| -43% | -$4.88M | ﹤0.01% | 2904 |
|
|
2016
Q3 | $14.4M | Buy |
56,022
+29,714
| +113% | +$7.65M | ﹤0.01% | 2149 |
|
|
2016
Q2 | $5.62M | Buy |
26,308
+1,846
| +8% | +$413K | ﹤0.01% | 2765 |
|
|
2016
Q1 | $5.04M | Sell |
24,462
-6,349
| -21% | -$1.22M | ﹤0.01% | 2718 |
|
|
2015
Q4 | $7.79M | Buy |
30,811
+5,456
| +22% | +$1.12M | ﹤0.01% | 2454 |
|
|
2015
Q3 | $4.17M | Sell |
25,355
-4,468
| -15% | -$790K | ﹤0.01% | 3049 |
|
|
2015
Q2 | $5.6M | Sell |
29,823
-7,929
| -21% | -$1.36M | ﹤0.01% | 2864 |
|
|
2015
Q1 | $6.23M | Buy |
37,752
+16,087
| +74% | +$3.31M | ﹤0.01% | 2689 |
|
|
2014
Q4 | $5.04M | Buy |
21,665
+1,206
| +6% | +$258K | ﹤0.01% | 2993 |
|
|
2014
Q3 | $3.7M | Sell |
20,459
-3,187
| -13% | -$610K | ﹤0.01% | 3325 |
|
|
2014
Q2 | $4.55M | Buy |
23,646
+3,021
| +15% | +$534K | ﹤0.01% | 3153 |
|
|
2014
Q1 | $3.75M | Buy |
20,625
+2,891
| +16% | +$572K | ﹤0.01% | 3353 |
|
|
2013
Q4 | $3.02M | Sell |
17,734
-7,267
| -29% | -$1.17M | ﹤0.01% | 3627 |
|
|
2013
Q3 | $3.92M | Buy |
25,001
+5,823
| +30% | +$1.08M | ﹤0.01% | 3204 |
|
|
2013
Q2 | $3.32M | Buy |
+19,178
| New | +$2.94M | ﹤0.01% | 3170 |
|
Other funds holding NKTR
BI
TSC
VCM
PM
AC
Goldman Sachs's NKTR Position: Q1 2026 in Review
Goldman Sachs reduced its Nektar Therapeutics (NKTR) stake by 14% in Q1 2026, selling an estimated $1.19M and leaving 126,942 shares worth $9.13M. The position accounts for ﹤0.01% of the portfolio, ranked #3143.
Goldman Sachs first reported a position in NKTR in Q2 2013 and has held it in 52 quarters since. The position peaked at $160M in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.
- Goldman Sachs held 126,942 shares of Nektar Therapeutics worth $9.13M as of Q1 2026.
- Goldman Sachs sold 20,851 Nektar Therapeutics shares in Q1 2026, an estimated $1.19M.
- Nektar Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3143 holding.
- Goldman Sachs first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 52 quarters since.
- Goldman Sachs's Nektar Therapeutics position peaked at $160M in Q1 2018.
- 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.